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Prof. Porta 
Dear colleagues, we present today a rare infection developed in an immunocompromised patient, 
which  represented a diagnostic challenge while admitted to our Internal Medicine ward. Dr. Gili, 
will you please describe the patient? 
 
Case presentation 
Dr. Gili 
A 71 year old man affected by chronic lymphatic leukemia, arrived in the emergency department 
with a swollen and tender right calf. The patient reported a 7 Kg weight loss over the previous 
month and his current therapy included antiviral (Acyclovir 400 mg bid) and trimethoprim-
sulfamethoxazole (160 mg twice weekly) prophylaxis, prednisone 25 mg/die and a proton pump 
inhibitor. 
Clinical examination showed normal vital parameters except for mild fever and confirmed swelling, 
approximately 8 cm in length, of the postero-medial region of right calf. Laboratory findings 
revealed mild anemia, elevated C reactive protein levels and procalcitonin within the normal range. 
A previously known lesion of the left lung appeared enlarged at chest X-Ray, and soft tissue 
echography interpreted the calf swelling as a large organizing hematoma of the medial 
gastrocnemius muscle. Antibiotic therapy with amoxicillin-clavulanate 2,2 gr iv tid and 
azithromycin 500 mg od was started, as superinfection of the hematoma and/or the pulmonary 
lesion was hypothesized, and the patient was admitted to our ward. 
A diagnosis of chronic lymphatic leukemia had been established in 2006 and the patient had 
received six cycles of chemo- and immunotherapy, comprehensive of some experimental protocols, 
but these had not been able to stop progression of the disease. One year before the current 
admission, following administration of the experimental drug idelalisib, a re-staging chest 
computed tomography (CT) had revealed a nodule, one centimeter in diameter, at the left 
pulmonary apex (Fig.1a) which the radiologists were unable to further characterize. Considering its 
relatively rapid development, the most plausible hypotheses were either a new neoplastic lesion or 
an intra-pulmonary lymph node. Among further microbiologic and imaging investigations, 
Quantiferon test and neoplasia markers (CEA/NSE/Cyfra21-1/cromogranina A) were indifferent, 
while a Positron Emission Tomography / Computed Tomography (PET/CT) scan documented 
intense accumulation of the radiotracer in correspondence of the nodule. To check if the lesion 
would respond to antimicrobial therapy, azythromicin was started on an empirical basis. 
CT scans had been repeated every three months over the following year to monitor the lesion, 
which continued to expand, reaching 6 cm in main diameter in August 2015 (Fig. 1b). The 
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haematologists in charge decided to interrupt treatment with Ofatutmumab and perform a 
bronchoscopy with broncho-alveolar lavage and trans-bronchial biopsy. Since cultural, cytological 
and histological examinations were all negative, a trans-parietal CT-guided biopsy was performed, 
which revealed an inflammatory pattern but no neoplastic cells. 
Meanwhile, the patient was admitted to our ward because of the calf lesion and, to complete the 
pulmonary diagnostic assessment, a new chest CT scan was performed, followed by a PET scan to 
better direct a new lung biopsy. An irregular pulmonary consolidation extended to the third 
posterior costal arch and the posterior thorax wall, corresponding to the site of the previous 
pulmonary biopsy. The trans-parietal CT-guided lung biopsy that followed confirmed an 
inflammatory pattern, without any clues to the nature of the lesion. An interdisciplinary consultation 
(hematologist, thoracic surgeon and internists) recommended that the lung lesion be surgically 
removed after resolution of the calf infection.   
Antibiotic therapy was continued but did not improve swelling and inflammation of the calf. A 
plastic surgeon was consulted. 
 
Dr. Baglioni 
The lesion had the appearance of a large, possibly superinfected, muscle hematoma but did not 
respond to usual therapies, including compression stockings, bed rest, lifting of the leg, or 
antimicrobial therapy. I drained the collection, obtaining abundant serum-hematic fluid and left a 
drainage on site (Fig. 2a-b-c). Fluid accumulation relapsed upon removal of the drainage, so that 
surgical debridement of the calf abscess was performed and the resulting open wound treated by 
negative pressure therapy, (V.A.C. therapy, KCI- Kci Medical Srl) until hospital discharge. 
 
Dr. Gili: 
While waiting for results of the fluid culture, the patient complained of worsening pain at the calf 
and fever at night. Samples for blood cultures were collected, while X-Ray and magnetic resonance 
ruled out osteomyelitis of the right calf. After 5 days, blood cultures did not grow any pathogens. A 
clinical suspicion of Nocardia infection was raised by the presence of macroscopic inclusions, 
resembling fungal hyphae, in the abscess fluid. Nocardia bacteria aggregate in filaments similar to 
hyphae and are common opportunistic pathogens in immunodepressed patients.  Therefore, the 
clinical presentation, the negative blood cultures and procalcitonin within the normal range [1], 
strengthened our suspicion and the microbiologists were alerted. Empirical antimicrobial treatment 
was continued until, after another 2 days, cultures identified the presence of Nocardia in the abscess 
fluid. An infective disease consultant was brought in. 
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Prof. De Rosa 
Nocardiosis is a granulomatous pyogenic infection caused by species belonging to the aerobic 
Actinomycetes group. Nocardia is a non-spore forming, gram-positive filamentous bacillus with 
hyphae-like branching. It is saprophytic and can be found in soil and water [2,3]. The main risk 
factor for infection is a defective immune system, consequent to diabetes, malignancies, HIV/AIDS, 
lung disorders, connective tissue disorders, alcoholism, transplant, and steroid therapy [4-6]. 
Species associated with human infection include the Nocardia asteroides complex (more than 50% 
of cases in humans), N. brasiliensis, N. abscessus, N. cyriacigeorgica, N. farcinica, N. nova and 
others. [2,4,5]. These bacteria are universally spread, being isolated worldwide in individuals of any 
age and equally in both sexes [4,5]. Differentiation of Nocardia species is not routinely performed 
in most laboratories, because the procedure is expensive and not expected to modify treatment. 
 
Prof. Porta 
How is the microbiological workout performed in the suspicion of nocardiosis? 
 
Prof. De Rosa 
Nocardia can be identified in biopsies, sputum, pus or CSF. Culture is performed with the BCYE 
medium (buffered agar with yeast and charcoal extracts) and the branching pseudo-hyphae are 
identified by Gram staining. Culture should be prolonged for at least two weeks. The forming 
colonies create rosary aggregates of Gram+ Nocardiae showing weak acid-resistance [2,3,7]. 
Differential diagnosis should consider other slow-developing pulmonary diseases such as fungal 
infections, aspergillosis, mucormycosis, histoplasmosis, blastomycosis, cryptococcosis, 
actinomycosis, mycobacterial infections, lung malignancies, lymphocutaneous diseases, superficial 
cellulitis, mycetoma, brain malignancies, abscesses or vascular infarctions [5]. 
 
Prof. Porta 
How ìs nocardiosis usually manifested? 
 
Dr. Chiacchiarini 
Clinical signs depend on the infection site. Inhalation may cause pulmonary nocardiosis, 
pneumonia, lung abscesses or cavitary lesions, with subclinical symptoms such as fatigue, low-
grade fever, shivering, cough, dyspnea, pleuritic pain, loss of weight. [4,5,7,8] Access of the 
bacteria via a cut or abraded skin causes cutaneous nocardiosis, that may occur also in non-
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immunocompromised patients and is characterized by cellulitis, ulcers, pyoderma, ulcerations or 
abscesses. The infection can spread from the skin to loco-regional lymph nodes or subcutaneous 
layers [5,9]. In immunocompromised patients it frequently disseminates to non-contiguous sites 
such as brain, kidneys, joints, heart, eyes, and bone. Consequently, neuroimaging and bone 
magnetic resonance should be performed in every patient affected by nocardiosis. [4-6] 
 
 
Dr. Morra di Cella 
To exclude systemic dissemination of the infection, a brain magnetic resonance was performed and 
a swab from the inflamed skin area at the site of the previous trans-parietal lung biopsy was sent for 
culture. Bilateral micro-abscesses in the cortex were detected and skin localization of Nocardia was 
confirmed. 
 
Prof. Porta 
What is the appropriate therapy for this condition? 
 
Prof. Brizzi 
If not treated, the infection may be fatal. The majority of patients respond, albeit slowly, to first-line 
therapy with trimethoprim-sulphamethoxazole (TMP-SMX) (trimethoprim dose: 2,5-5 mg/kg bid 
per os or 15 mg/kg tid ev) [4,5]. The drug has excellent penetration into most tissue compartments, 
including the central nervous system, and reaches high serum concentrations even after oral 
administration [4]. Concern is growing following recent reports of sulfonamide resistance, 
especially in Nocardia farcinica [5,10,11]. Alternatives in case of resistance or allergy to 
sulfonamides are amikacin (7,5 mg/kg bid), imipenem (500 mg every 6 hours), ceftriaxone, and 
linezolid [4,12]. Duration of therapy depends on the site of infection and presence of 
immunodeficiency. 
One to three months of oral TMP-SMX or amoxicillin-clavulanate are sufficient to treat mild 
cutaneous infections, extended to 6-12 months in immunocompromised patients. Combined therapy 
with TMP-SMX (15 mg/kg iv of trimetoprim in 2-4 doses/die) and amikacin (7.5 mg/kg iv every 12 
h) is recommended in severe pulmonary or disseminated infections and in immunocompromised 
patients. An alternative is imipenem (500 mg iv every 6 hours) plus amikacin. If the brain is 
involved, TMP-SMX is the therapy of choice, with imipenem and a third generation cephalosporin 
(ceftriaxone 2 g every 12 hours), in association with amikacin if multi-organ infection is present. 
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There are few experiences with linezolid, showing high degree of success, especially if the central 
nervous system is involved [14]. 
Surgical drainage of abscesses with careful debridement and wound drainage are indicated 
[4,5,12,13]. After 3-6 weeks of iv treatment it is possible to shift to oral therapy, which should be 
continued for 6-12 months if the infection is disseminated or the brain is involved. 
Immunocompromised patients may also require prolonged iv therapy, up to 3-6 months [4,5,12,13]. 
 
 
Dr. Chiacchiarini 
We reached a final diagnosis of disseminated nocardiosis involving the lung, skin, deep soft tissues 
and, possibly, brain micro-abscesses in an immunocompromised patient affected by chronic 
lymphatic leukemia on steroid therapy. Antimicrobial therapy with i.v. trimethoprim-
sulphamethoxazole (trimethoprim 15 mg/kg) tid was started. 
 
Dr. Morra di Cella 
After one month of antimicrobial therapy a CT scan of the thorax revealed significant reduction in 
size of the lesion at the left pulmonary apex, but the lymphoproliferative pathology was rapidly 
progressing with significant increase in volume of supra- and infra diaphragmatic lymph nodes. The 
calf was improving, after surgical debridement combined with antimicrobial therapy. The patient 
was discharged from hospital and continued VAC therapy and oral TMP-SMX at home. His 
conditions remained stable for three months, but then fever and calf tenderness and swelling 
reappeared. The patient was re-admitted to our division and re-staging of the infection was 
performed. The lung lesion presented complete fibrotic involution, the lymphadenopaties were 
stable in appearance and the brain micro-abscesses had completely disappeared. However, 
inflammation and fluid collection were still present in the calf. A new surgical procedure was 
performed, with removal of the medial gastrocnemius muscle followed by a new course of VAC 
therapy. 
Prof. De Rosa 
The subcutaneous infection had relapsed despite continuous TMP-SMX therapy and cultures from 
surgical drainage were now positive for Cotrimoxazole-resistant Nocardia. My advice was to start 
cefepime 2 g tdi and amikacin 7,5 mg/Kg bid iv for the first 15 days, to be replaced with ceftriaxone 
at discharge [5,6]. 
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Dr. Morra di Cella 
This last regimen administered finally eradicated the infection from the soft tissues of the calf. After 
two months of the new treatment the drainage was removed and local signs of inflammation had 
disappeared, so that antimicrobial therapy could be interrupted. Treatment for the hematological 
disease could now be re-started. 
 
Prof. Brizzi 
A seventh line therapy with Ibrutinib was started with excellent results. Hematopoiesis 
progressively improved until periodic blood transfusions were no longer necessary, 
lymphadenopathies regressed and the infection did not reappear. 
 
Prof. Porta 
A brief commentary is in order to sum up this case. As nocardiosis is quite rare, it is difficult to 
suspect and diagnose. Clinical signs are non-specific and the bacterium grows slowly and only in 
particular culture media. Clinicians should suspect nocardiosis in immunocompromised patients 
presenting with pulmonary and/or cutaneous infections. The appropriate duration of antimicrobial 
therapy and the threat of antibiotic resistance must also be kept in mind. Usually, patients with 
hematological neoplasia receive TMP-SMX prophylaxis, which is effective in the prevention of 
Pneumocystis pneumonia but decrease the risk of nocardial infection only if assumed daily. 
Intermittent regimens (2 double-strength tablets twice weekly or 1 single strength tablet 3 times 
weekly) are less protective. [5] Unfortunately, our patient had not been under TMP-SMX 
prophylaxis while treated with biologic agents for his leukemia. 
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Figure legends: 
 
Fig.1. CT-scan evolution of the lesion of the left pulmonary apex from first detection (left) to ten 
months later (right). 
 
Fig. 2. From left to right: Appearance of the fluid drained from the calf lesion; X-Ray confirming 
correct placement of the drainage; collection bag with the full amount of drained fluid. 
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Fig.1. CT-scan evolution of the lesion of the left pulmonary apex from first detection (left) to ten 
months later (right). 
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Fig. 2. From left to right: Appearance of the fluid drained from the calf lesion; X-Ray confirming 
correct placement of the drainage; collection bag with the full amount of drained fluid. 
 
 
   
 
 
 
 
 
